AbbVie (ABBV) Quick Ratio: History & Chart

AbbVie Inc. (ABBV)ABBVAbbVie Inc.

About AbbVie Inc.

AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.

North Chicago, IL

57,000 employees

www.abbvie.com

Healthcare / Drug Manufacturers - General

Sector: Healthcare
Industry: Drug Manufacturers - General
CEO: Robert A. Michael

View full financials

ABBV Quick Ratio (Acid-Test) Metrics

QUICK RATIO (ACID-TEST)

0.68

QUICK RATIO (ACID-TEST) AVG TTM

0.62

QUICK RATIO (ACID-TEST) AVG 3Y

0.69

QUICK RATIO (ACID-TEST) AVG 5Y

0.72

QUICK RATIO (ACID-TEST) AVG 10Y

0.91

QUICK RATIO (ACID-TEST) AVG 15Y

1.12

QUICK RATIO (ACID-TEST) AVG 20Y

N/A

CURRENT VS TTM AVG

+9.83%

CURRENT VS 3Y AVG

-1.29%

CURRENT VS 5Y AVG

-6.32%

CURRENT VS 10Y AVG

-25.46%

CURRENT VS 15Y AVG

-39.82%

CURRENT VS 20Y AVG

N/A

SECTOR MEDIAN · HEALTHCARE

1.21

median of 79 covered companies

CURRENT VS SECTOR MEDIAN

-44.09%

vs the sector median at left

NAME	MARKET CAP	QUICK RATIO (ACID-TEST)	TTM	3Y	5Y
AbbVie Inc. (ABBV)	$443.24B	0.68	0.62	0.69	0.72
UnitedHealth Group Incorporated (UNH)vs ›	$376.34B	0.79	0.81	0.80	0.79
Merck & Co., Inc. (MRK)vs ›	$321.62B	1.30	1.23	1.17	1.09
Johnson & Johnson (JNJ)vs ›	$617.78B	0.77	0.81	0.84	0.91
Thermo Fisher Scientific Inc. (TMO)vs ›	$213.42B	1.53	1.41	1.34	1.37
Novo Nordisk A/S (NVO)vs ›	$209.19B	0.57	0.56	0.61	0.63
Amgen Inc. (AMGN)vs ›	$207.87B	0.90	0.93	1.02	1.14
Abbott Laboratories (ABT)vs ›	$184.11B	1.18	1.21	1.20	1.26
Gilead Sciences, Inc. (GILD)vs ›	$161.66B	1.31	1.38	1.29	1.26
Pfizer Inc. (PFE)vs ›	$142.54B	0.87	0.90	0.87	0.95

NAME

MARKET CAP

QUICK RATIO (ACID-TEST)

TTM

AbbVie Inc. (ABBV)

$443.24B

0.68

0.62

0.69

0.72

UnitedHealth Group Incorporated (UNH)vs ›

$376.34B

0.79

0.81

0.80

0.79

Merck & Co., Inc. (MRK)vs ›

$321.62B

1.30

1.23

1.17

1.09

Johnson & Johnson (JNJ)vs ›

$617.78B

0.77

0.81

0.84

0.91

Thermo Fisher Scientific Inc. (TMO)vs ›

$213.42B

1.53

1.41

1.34

1.37

Novo Nordisk A/S (NVO)vs ›

$209.19B

0.57

0.56

0.61

0.63

Amgen Inc. (AMGN)vs ›

$207.87B

0.90

0.93

1.02

1.14

Abbott Laboratories (ABT)vs ›

$184.11B

1.18

1.21

1.20

1.26

Gilead Sciences, Inc. (GILD)vs ›

$161.66B

1.31

1.38

1.29

1.26

Pfizer Inc. (PFE)vs ›

$142.54B

0.87

0.90

0.87

0.95

Quick Ratio (Acid-Test) FAQ

What is the quick ratio (acid-test) for AbbVie Inc. (ABBV)?

The quick ratio (acid-test) for ABBV stock is 0.68.

Is AbbVie Inc.'s quick ratio (acid-test) high or low?

The quick ratio (acid-test) of 0.68 is in line with its 5-year average of 0.72, around the middle of its 5-year range (0.54–0.91).

What is the TTM average quick ratio (acid-test) for AbbVie Inc. (ABBV)?

The TTM average quick ratio (acid-test) for ABBV stock is 0.62.

What is the 3Y average quick ratio (acid-test) for AbbVie Inc. (ABBV)?

The 3Y average quick ratio (acid-test) for ABBV stock is 0.69.

What is the 5Y average quick ratio (acid-test) for AbbVie Inc. (ABBV)?

The 5Y average quick ratio (acid-test) for ABBV stock is 0.72.

What is the 10Y average quick ratio (acid-test) for AbbVie Inc. (ABBV)?

The 10Y average quick ratio (acid-test) for ABBV stock is 0.91.

What is the 15Y average quick ratio (acid-test) for AbbVie Inc. (ABBV)?

The 15Y average quick ratio (acid-test) for ABBV stock is 1.12.

DATE	QUICK RATIO (ACID-TEST)
2026-03-31	0.68
2025-12-31	0.56
2025-09-30	0.60
2025-06-30	0.61
2025-03-31	0.64
2024-12-31	0.55
2024-09-30	0.54
2024-06-30	0.71
2024-03-31	0.83
2023-12-31	0.76
2023-09-30	0.84
2023-06-30	0.77
2023-03-31	0.82
2022-12-31	0.84
2022-09-30	0.83
2022-06-30	0.75
2022-03-31	0.71
2021-12-31	0.70
2021-09-30	0.91
2021-06-30	0.79
2021-03-31	0.73
2020-12-31	0.73
2020-09-30	0.81
2020-06-30	0.70
2020-03-31	3.03
2019-12-31	3.06
2019-09-30	1.04
2019-06-30	0.78
2019-03-31	0.91
2018-12-31	0.89
2018-09-30	1.08
2018-06-30	0.71
2018-03-31	1.10
2017-12-31	1.18
2017-09-30	1.32
2017-06-30	1.25
2017-03-31	1.60
2016-12-31	1.51
2016-09-30	1.61
2016-06-30	1.62
2016-03-31	1.39
2015-12-31	1.34
2015-09-30	1.82
2015-06-30	1.35
2015-03-31	1.30
2014-12-31	1.31
2014-09-30	2.49
2014-06-30	2.65
2014-03-31	2.61
2013-12-31	2.43
2013-09-30	2.24
2013-06-30	2.14
2013-03-31	2.05
2012-12-31	2.10
2012-09-30	1.86
2012-06-30	1.06
2012-03-31	1.06
2011-12-31	1.10
2011-09-30	0.00
2011-06-30	0.00
2011-03-31	0.00

DATE

QUICK RATIO (ACID-TEST)

2026-03-31

0.68

2025-12-31

0.56

2025-09-30

0.60

2025-06-30

0.61

2025-03-31

0.64

2024-12-31

0.55

2024-09-30

0.54

2024-06-30

0.71

2024-03-31

0.83

2023-12-31

0.76

2023-09-30

0.84

2023-06-30

0.77

2023-03-31

0.82

2022-12-31

0.84

2022-09-30

0.83

2022-06-30

0.75

2022-03-31

0.71

2021-12-31

0.70

2021-09-30

0.91

2021-06-30

0.79

2021-03-31

0.73

2020-12-31

0.73

2020-09-30

0.81

2020-06-30

0.70

2020-03-31

3.03

2019-12-31

3.06

2019-09-30

1.04

2019-06-30

0.78

2019-03-31

0.91

2018-12-31

0.89

2018-09-30

1.08

2018-06-30

0.71

2018-03-31

1.10

2017-12-31

1.18

2017-09-30

1.32

2017-06-30

1.25

2017-03-31

1.60

2016-12-31

1.51

2016-09-30

1.61

2016-06-30

1.62

2016-03-31

1.39

2015-12-31

1.34

2015-09-30

1.82

2015-06-30

1.35

2015-03-31

1.30

2014-12-31

1.31

2014-09-30

2.49

2014-06-30

2.65

2014-03-31

2.61

2013-12-31

2.43

2013-09-30

2.24

2013-06-30

2.14

2013-03-31

2.05

2012-12-31

2.10

2012-09-30

1.86

2012-06-30

1.06

2012-03-31

1.06

2011-12-31

1.10

2011-09-30

0.00

2011-06-30

0.00

2011-03-31

0.00

Quick Ratio (Acid-Test): 0.68

ABBV Quick Ratio

ABBV Average Quick Ratio (Acid-Test) Chart

ABBV Current vs Average Quick Ratio (Acid-Test) Chart

ABBV Quick Ratio (Acid-Test) Metrics

ABBV Competitors' Quick Ratio (Acid-Test)

Liquidity Comparison

Quick Ratio (Acid-Test) Formula & Definition

Quick Ratio (Acid-Test) FAQ

ABBV Quick Ratio (Acid-Test) History

Related Metrics